Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. reports company news on its gene therapy pipeline, regulatory interactions, clinical data, operating results, and capital structure. The company develops genetic medicines for severe diseases, with disclosed programs including AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, ALS programs, and an approved gene therapy for hemophilia B.
Recurring updates cover FDA and MHRA discussions, clinical-trial observations, exploratory efficacy and safety data, quarterly and annual financial results, debt financing arrangements, corporate presentations, and governance or shareholder matters tied to its Nasdaq-listed public-company status.
uniQure (NASDAQ: QURE) announced the treatment of the first two patients in its Phase I/II clinical trial for AMT-130, aimed at Huntington’s disease. This double-blind study, involving 26 patients, will assess safety, tolerability, and efficacy signals. One patient received AMT-130 while the other underwent sham surgery. The trial features an 18-month core study followed by long-term follow-ups. The innovative delivery method involves MRI-guided surgery. This milestone reflects uniQure's commitment to developing effective therapies for Huntington’s disease, a condition with no currently approved treatments.
uniQure N.V. has appointed Leonard E. Post, Ph.D., to its Board of Directors, enhancing its research leadership. Dr. Post, with over 35 years in biotechnology, will also chair the Research & Development Committee. His past roles include significant positions at BioMarin and Onyx Pharmaceuticals, focusing on gene therapy. This strategic move aims to bolster uniQure's pipeline, particularly in preparing for marketing authorization of etranacogene dezaparvovec for hemophilia B. This leadership change reflects a commitment to advancing innovative therapies for severe medical conditions.
uniQure N.V. (NASDAQ: QURE) announced a virtual format for its 2020 Annual General Meeting on June 17, 2020, due to COVID-19 concerns. Shareholders of record as of May 20, 2020, can participate via a virtual meeting platform but cannot vote in real-time or attend in person. The meeting’s details can be accessed through the uniQure website. The company is focused on advancing gene therapy treatments for severe genetic diseases, including hemophilia and Huntington’s disease.
Summary not available.
Summary not available.